Nintedanib Clonmel (Nintedanib)

Nintedanib is indicated for fibrotic lung disorders and certain cancers, acting on pathways that drive fibroblast activity and tumor angiogenesis.

• Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in forced vital capacity.
• Systemic sclerosis‑associated interstitial lung disease: improves lung function and delays worsening.
• Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and spread.

• Nintedanib inhibits multiple receptor tyrosine kinases—including VEGFR, PDGFR and FGFR—thereby blocking signaling pathways that promote fibroblast proliferation, migration, and transformation, as well as angiogenesis. This multi‑target inhibition reduces fibrotic tissue formation and tumor vascularization, contributing to its antifibrotic and antineoplastic effects.

Nintedanib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Diarrhea: frequent loose stools.
• Nausea: feeling of sickness.
• Vomiting: expulsion of stomach contents.
• Abdominal pain: discomfort in the stomach area.
• Elevated liver enzymes: increased ALT/AST levels.
• Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury.
• Bleeding events: gastrointestinal or other hemorrhage.
• Cardiovascular events: myocardial infarction or stroke.
• Severe infections: opportunistic or bacterial infections.
• Pulmonary embolism: clot in lung vessels.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for potential complications.

• Liver function monitoring: check ALT, AST, and bilirubin regularly.
• Cardiovascular assessment: evaluate risk of ischemic events.
• Bleeding risk: avoid concomitant anticoagulants unless necessary.
• Gastrointestinal health: monitor for severe diarrhea or bleeding.
• Pregnancy and lactation: use only if benefits outweigh risks.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin): heightened bleeding risk.
• Antiplatelet agents: additive hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors: may modestly raise plasma levels.
• P‑glycoprotein substrates: possible altered absorption.
• NSAIDs: increased gastrointestinal bleeding risk.
• Diuretics: monitor for dehydration if severe diarrhea occurs.